Prescribers remain cautious about substituting generic drugs for narrow therapeutic index (NTI) medications like warfarin and levothyroxine due to risks of instability, inconsistent communication, and fragmented state laws-even as generics prove clinically equivalent in most cases.
Pharmaceutical equivalence ensures generic drugs have the same active ingredient, dose, and form as brand-name drugs. It's the first step to safe, affordable substitution-but it's not the whole story.
False advertising in generic drugs misleads patients, endangers health, and violates federal law. Learn the rules, risks, and real consequences of deceptive marketing in the $140 billion generic drug market.
